Plus Therapeutics (NASDAQ:PSTV) Earns Hold Rating from D. Boral Capital

Plus Therapeutics (NASDAQ:PSTV)‘s stock had its “hold” rating reissued by analysts at D. Boral Capital in a research report issued to clients and investors on Tuesday,Benzinga reports.

PSTV has been the topic of a number of other research reports. HC Wainwright reissued a “buy” rating and set a $1.00 price objective (down from $2.00) on shares of Plus Therapeutics in a report on Friday, January 23rd. Lake Street Capital started coverage on shares of Plus Therapeutics in a research note on Tuesday, February 3rd. They issued a “buy” rating and a $2.00 target price for the company. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Thursday, January 22nd. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Plus Therapeutics presently has an average rating of “Hold” and a consensus price target of $5.60.

Plus Therapeutics Stock Performance

Plus Therapeutics stock traded down $0.04 on Tuesday, reaching $0.17. The company’s stock had a trading volume of 15,615,860 shares, compared to its average volume of 9,662,363. The business’s fifty day moving average price is $0.27 and its 200 day moving average price is $0.46. The company has a market cap of $29.34 million, a price-to-earnings ratio of -0.14 and a beta of 0.78. Plus Therapeutics has a twelve month low of $0.16 and a twelve month high of $1.22.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Scientech Research LLC acquired a new position in Plus Therapeutics in the third quarter valued at about $100,000. Altium Capital Management LLC bought a new stake in shares of Plus Therapeutics in the 3rd quarter valued at about $628,000. Susquehanna International Group LLP acquired a new stake in shares of Plus Therapeutics in the 3rd quarter valued at approximately $46,000. Jane Street Group LLC bought a new position in Plus Therapeutics during the 4th quarter worth approximately $525,000. Finally, Geode Capital Management LLC grew its holdings in Plus Therapeutics by 72.5% during the fourth quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock valued at $719,000 after purchasing an additional 589,544 shares during the period. 3.28% of the stock is currently owned by institutional investors.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.